Saturday 17 October 2026
Export CNMD’s income statement to Excel — free account
CONMED Corporation
CNMD Healthcare Medical Devices
CONMED Corporation’s revenue for fiscal 2025 (year ended December 2025) was $1.4 billion, up 5.18% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 11.6%, free cash flow grew 46.0% and total debt fell 5.40%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five, operating cash flow growth for three.
46.72
0.42
−0.89%
Follow CNMD
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
22.83 | 26.89 | 19.98 | 17.69 |
P/S ratio |
1.08 | 0.92 | 0.79 | 0.72 | |
P/FCF ratio |
9.77 | 8.35 | 8.74 | 7.32 | |
P/Operating CF |
27.12 | 27.19 | 80.28 | 26.53 | |
P/B ratio |
1.44 | 1.22 | 1.06 | 0.95 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
1.69 | 1.49 | 1.39 | 1.30 | |
EV/EBITDA |
11.50 | 11.25 | 9.91 | 9.33 | |
EV/Operating CF |
13.54 | 12.03 | 13.37 | 11.83 | |
EV/FCF |
15.24 | 13.61 | 15.42 | 13.25 | |
Quick Ratio |
0.84 | 0.92 | 0.90 | 0.61 | |
Current Ratio |
2.10 | 2.14 | 2.29 | 1.48 | |
Net Debt/EBITDA |
25.65 | 13.93 | 18.14 | 14.10 | |
Debt/Assets |
36.76% | 35.90% | 37.19% | 36.27% | |
Debt/Equity |
0.85 | 0.81 | 0.85 | 0.80 | |
Asset Turnover |
0.58 | 0.59 | 0.59 | 0.59 | |
Operating CF/Net income |
18.78 | 2.77 | 0.97 | 1.61 | |
Capex/Depreciation |
(0.26) | (0.25) | (0.14) | (0.15) | |
Interest Coverage |
1.56 | 4.97 | 3.60 | 4.62 | |
Research and Development Expense of Revenue |
4.11% | 3.99% | 5.15% | 4.51% | |
Selling, General and Administrative Expense of Revenue |
41.53% | 44.68% | 44.69% | 42.37% | |
Intangible Assets out of Total Assets |
0.60 | 0.60 | 0.60 | 0.59 | |
Share Based Compensation of Revenue |
1.36% | 1.33% | 1.74% | 1.52% | |
Graham Net Nets |
(0.45) | (0.49) | (0.58) | (0.59) | |
Graham Number |
38.86 | 33.63 | 36.40 | 37.97 | |
Earnings Yield |
4.38% | 3.72% | 5.01% | 5.65% | |
Free Cash Flow Yield |
10.23% | 11.97% | 11.44% | 13.66% | |
Revenue per Share |
10.92 | 12.02 | 10.37 | 11.42 | |
Operating CF per Share |
1.73 | 1.49 | 0.44 | 1.23 | |
Capex per Share |
(0.17) | (0.16) | (0.09) | (0.10) | |
Free Cash Flow per Share |
1.57 | 1.33 | 0.35 | 1.14 | |
Cash per Share |
1.26 | 1.32 | 1.15 | 1.24 | |
Shareholders Equity per Share |
32.57 | 33.29 | 33.27 | 34.63 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
32.57 | 33.29 | 33.27 | 34.63 | |
Free Cash Flow |
48.50 | 41.22 | 10.58 | 34.16 | |
Working Capital |
347.46 | 357.82 | 377.88 | 220.27 | |
Capital Expenditures |
(5.19) | (5.11) | (2.89) | (2.93) | |
Net Current Asset Value |
(652.07) | (619.79) | (626.68) | (583.25) | |
EV/EBIT |
19.16 | 20.02 | 17.02 | 16.14 | |
Capex to Sales |
0.02 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
12.29 | 12.28 | 9.65 | 8.92 | |
| Other line items | |||||
Average Receivables |
228.09 | 242.78 | 224.90 | 236.96 | |
Average Payables |
105.83 | 97.95 | 100.57 | 101.04 | |
Average Inventory |
353.45 | 351.13 | 360.39 | 361.22 | |
Average Assets |
2,319.12 | 2,316.00 | 2,306.31 | 2,314.38 | |
Average Common Equity |
970.58 | 997.89 | 997.65 | 1,022.13 |
Columns are period end dates